NRX-101 Expanded Access

NCT05779267 | Unknown

• 1 other identifier: NRX101-012 EAP
• Study Type: expanded_access
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this Expanded Access Treatment Protocol is to make NRX-101 available to patients who have treatment-resistant depression and who are unable to participate in, or do not have access to, the ongoing NRX-101 clinical trial. The objective of the program is to provide treatment access while monitoring safety in the context of NRX-101 administration paired with theta burst transcranial magnetic stimulation..

Conditions

Treatment-Resistant Depression

Keywords

cycloserine; NMDA antagonist; NRX-101; transcranial magnetic stimulation

Interventions

NRX-101 DRUG

D-cycloserine/lurasidone fixed dose combination

Transcranial Magnetic Stimulation Sham DEVICE

transcranial magnetic stimulation will be employed and has shown effect in this population

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• years of age or older
• Able to understand the study procedures and risks and able to provide written and dated informed consent before any protocol-specific procedure.
• In the investigator's judgment, likely to comply with the Expanded Access Protocol, including transcranial magnetic stimulation visits, NRX-101 dosing instructions, scheduled assessments, and prompt communication of adverse events and other clinically important information.
• Under the care of a board-certified psychiatrist or other qualified psychiatric prescriber who has completed protocol-specific training, is registered as an investigator for this Expanded Access Protocol, and agrees to direct and document the patient's psychiatric care according to standard of care.
• Diagnosed with treatment resistant depression (TRD) according to the criteria defined in the DSM-5. This diagnosis must be made by a psychiatrist or other qualified licensed psychiatric provider.
• History of inadequate response, intolerance, or loss of effect to at least one prior adequate pharmacologic treatment for the current depressive episode with a medication indicated for treatment-resistant depression in the investigator's judgment.
• Planned course of theta burst transcranial magnetic stimulation as part of standard clinical care for the current depressive episode, to be delivered at a site with appropriate experience and safety procedures for transcranial magnetic stimulation.
• No uncontrolled or unstable medical condition that, in the investigator's judgment, creates an unacceptable risk with theta burst transcranial magnetic stimulation in combination with NRX-101 or prevents adequate assessment of safety.
• If heterosexual female, a status of non-childbearing potential or use of an acceptable form of birth control per the following criteria, and agrees to continue use of the same method of birth control for the duration of treatment with NRX-101:
• Non-childbearing potential: physiologically incapable of becoming pregnant (i.e., permanently sterilized \[status post-hysterectomy, bilateral tubal ligation\], or post-menopausal with last menses at least one year prior to Screening); or
• Childbearing potential, and meets the following criteria:
• i. Use of any form of hormonal birth control for at least 2 months prior to Screening, on hormone replacement therapy that started prior to 12 months of amenorrhea, using an intrauterine device (IUD) for at least 1 month prior to Screening, in a monogamous relationship with a partner who has had a vasectomy, or sexually abstinent.
• ii. Negative urinary pregnancy test at Screening, confirmed by a second negative urinary pregnancy test at Day 1, prior to receiving treatment with NRX-101.
• Sufficient stability of residence and contact information to allow appropriate follow up and emergency contact during participation in the Expanded Access Protocol, in the investigator's judgment.

You may not qualify if:

• Heterosexual female of childbearing potential who is not willing to use one of the specified forms of birth control during the study.
• Female who is pregnant (positive pregnancy test at Screening) or breastfeeding.
• Active suicidality (without the intention to act) as evidenced by a score of \>3 on the Columbia Suicide Severity Rating Scale.
• Current DSM-5 diagnosis of moderate or severe substance use disorder (except marijuana or tobacco use disorder) within the 12 months prior to Screening. (Note: Substance use disorder cannot be the precipitant for study entry).
• Current DSM-5 diagnosis of alcohol use disorder
• A lifetime history of phencyclidine (PCP)/ketamine drug abuse
• History of schizophrenia or schizoaffective disorder
• History of anorexia nervosa, bulimia nervosa, eating disorder not otherwise specified (NOS), or other specified feeding and eating disorders (OSFED) within 3 years of Screening.
• Has dementia, delirium, amnestic, or any other cognitive disorder.
• Renal impairment defined as estimated glomerular filtration rate (eGFR) \< 60 mL/min, calculated using the 2021 CKD-EPI creatinine equation (race-free).
• Clinically significant hepatic impairment. Clinically significant hepatic impairment is defined as a history of chronic liver disease (e.g., cirrhosis, chronic hepatitis, alcoholic liver disease, nonalcoholic steatohepatitis) or evidence at Screening of acute liver disease or impaired liver function (e.g., ALT or AST \>3 × ULN, total bilirubin \>2 × ULN) or in the opinion of the Investigator.
• A clinically significant abnormality on the Screening physical examination that may affect safety or study participation, or that may confound interpretation of study results according to the study clinician.
• Risk factors for neurocardiogenic syncope including history of syncope/ presyncope related to noxious stimuli, anxiety, micturation, or posture.
• Co-morbidities as ascertained by medical history, physical examination (including measurement of vital signs), clinical laboratory evaluations, and electrocardiogram (ECG) which might interfere with compliance or the ability to assess efficacy or safety.
• Diagnosis of moderate to severe heart disease or current episode of:

Sponsors & Collaborators

• NeuroRx, Inc.: lead

Study Sites (1)

Harvard Mclean Hospital

Belmont, Massachusetts, 02478, United States

AVAILABLE

MeSH Terms

Conditions

Depressive Disorder, Treatment-Resistant

Condition Hierarchy (Ancestors)

Depressive Disorder; Mood Disorders; Mental Disorders

Study Officials

• Jonathan C Javitt, MD, MPH

  NRx Pharma, Inc.

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Adriana Manari

CONTACT

786-285-7655; amanari@nrxpharma.com

Jeff Heckman, MBA

CONTACT

4848020087; jheckman@nrxpharma.com

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 8, 2023
• First Posted: March 22, 2023
• Last Updated: July 20, 2026

Record last verified: 2026-07

Locations

US (1)